BioSpace News Archive

sp3nw to Accelerate WSU Life Science Innovation and Entrepreneurship Into Biotech, Pharma, Diagnostics, and Medical Device Companies Through Faculty, Affiliate Expertise

CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for Medicare and Medicaid Services (CMS) granted approval for a transitional pass-through (TPT) payment for BAROSTIM Therapy as part of the 2021 Outpatient Prospective Payment System (OPPS) Final Rule issued December 2, 202

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de Nantes) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104

BIOMODEX®, a pioneering digital health company that offers unique and enhanced 3D printed solutions for patient-specific rehearsal and physician training, today announced the appointment of Bill Perusek as Vice President of U.S. Sales.

Amgen (NASDAQ:AMGN) will host a webcast call for the investment community on Tuesday, Dec. 8, at 4:00 p.m. ET following the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. David M. Reese, M.D., executive vice president of Research and Development at Amgen

IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (“IN8bio” or the “Company”), today announced an upcoming presentation that provides an update of the ongoing Phase I clinical trial of their product candidate INB-100 at the 62nd American Society of Hematology Annual Meeting & Exposition

The Lupus Research Alliance is proud to announce the 2020 recipients of its Lupus Mechanisms and Targets Award (LMTA).

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the BMO 2020 Growth & ESG Conference on Wednesday, December 9, 2020 at 3:00 p.m. ET.

Bringing the comfort of a personal movie theater into the MRI scanning procedure.

Tevard Biosciences, and Zogenix (Nasdaq: ZGNX), today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.